Back to Home
This Programs has 2 events, beginning on 07:00AM - 07:30AM
Acute Myeloid Leukemia: Evidence-Based Guidance on Current Paradigms and New Therapeutic Approaches
Join us for this live, CME-certified symposium featuring review and discussion of patient case studies and key clinical trial data by renowned clinical experts providing their perspectives on recent advances in the treatment of AML
Sign up now! Registration is Complimentary
Friday Satellite Symposium on Acute Myeloid Leukemia: Evidence-Based Guidance on Current Paradigms and New Therapeutic Approaches, preceding the 63rd ASH Annual Meeting and Exposition.
To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.
07:00AM - 07:30AM
Breakfast and Registration
07:30AM - 07:45AM
Welcome and Program Overview
07:45AM - 08:30AM
In this episode, Fidelia Bernice, PharmD, and Aadia I. Rana, MD, share insights on HIV ART safety and tolerability including recent data on nephrotoxicity
8:30 AM – 9:15 AM
Clinical Discussion 2: Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
9:15 AM – 9:45 AM
New and Novel Advances in AML Therapeutics—Future Approaches to BMT and Targeted Therapies
9:45 AM – 10:00 AM
Final Thoughts and Audience Question and Answer
07:00AM - 07:30AM
Breakfast and Registration
07:30AM - 07:45AM
Welcome and Program Overview
07:45AM - 08:30AM
In this episode, Fidelia Bernice, PharmD, and Aadia I. Rana, MD, share insights on HIV ART safety and tolerability including recent data on nephrotoxicity
8:30 AM – 9:15 AM
Clinical Discussion 2: Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
9:15 AM – 9:45 AM
New and Novel Advances in AML Therapeutics—Future Approaches to BMT and Targeted Therapies
9:45 AM – 10:00 AM
Final Thoughts and Audience Question and Answer
07:00AM - 07:30AM
Breakfast and Registration
07:30AM - 07:45AM
Welcome and Program Overview
07:45AM - 08:30AM
In this episode, Fidelia Bernice, PharmD, and Aadia I. Rana, MD, share insights on HIV ART safety and tolerability including recent data on nephrotoxicity
8:30 AM – 9:15 AM
Clinical Discussion 2: Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
9:15 AM – 9:45 AM
New and Novel Advances in AML Therapeutics—Future Approaches to BMT and Targeted Therapies
9:45 AM – 10:00 AM
Final Thoughts and Audience Question and Answer
07:00AM - 07:30AM
Breakfast and Registration
07:30AM - 07:45AM
Welcome and Program Overview
07:45AM - 08:30AM
In this episode, Fidelia Bernice, PharmD, and Aadia I. Rana, MD, share insights on HIV ART safety and tolerability including recent data on nephrotoxicity
8:30 AM – 9:15 AM
Clinical Discussion 2: Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
9:15 AM – 9:45 AM
New and Novel Advances in AML Therapeutics—Future Approaches to BMT and Targeted Therapies
9:45 AM – 10:00 AM
Final Thoughts and Audience Question and Answer
07:00AM - 07:30AM
Breakfast and Registration
07:30AM - 07:45AM
Welcome and Program Overview
07:45AM - 08:30AM
In this episode, Fidelia Bernice, PharmD, and Aadia I. Rana, MD, share insights on HIV ART safety and tolerability including recent data on nephrotoxicity
8:30 AM – 9:15 AM
Clinical Discussion 2: Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
9:15 AM – 9:45 AM
New and Novel Advances in AML Therapeutics—Future Approaches to BMT and Targeted Therapies
9:45 AM – 10:00 AM
Final Thoughts and Audience Question and Answer
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
Supported by an independent educational grant from
AbbVie
Supported by an educational grant from Genentech, a member of the Roche Group
Supported by an independent medical education grant from Bristol Myers Squibb